Perspective on the Treatment of Advanced Renal Cell Cancer - Episode 4
Robert J. Motzer, MD:The treatment paradigm changed away from cytokine therapy to sunitinib in 2006, based on the study that compared sunitinib to interferon alpha. Since then, there have been other drugs that have been developed as first-line therapy, but for the most part, sunitinib has always been considered the reference standard for efficacy and for first-line treatment for renal cell cancer. So, sunitinib and pazopanib have been the two most commonly used TKIs in first-line therapy.
More recently, there has been a change, in that there have been studies that compared cabozantinib to sunitinib in intermediate/poor-risk patients in the first-line setting, suggesting that cabozantinib is superior to sunitinib. And there was a large phase III trial that compared ipilimumab plus nivolumab to sunitinib in first-line therapy, and this showed a survival benefit for the intermediate and poor-risk group. These are 2 new treatments that are now available to oncologists, and in certain respects we feel will replace sunitinib over time.
Between 35% and 40% of patients that are treated with sunitinib in first-line therapy will achieve an objective response. Generally, the objective responses are partial, as in this patient. The median progression-free survival to sunitinib, and most serious has been between 9 and 11 months. So this patient’s time on therapy, and time to progression were the average of what we anticipate to see with most patients with metastatic renal cancer.
There is little data that we know of that translates to why tumors become resistant to sunitinib and some of the other VEGF TKIs. There have been some proposed mechanisms of angiogenic escape. One is through the MET pathway, and another is through FGF overexpression. Some of the newer VEGF TKIs, they targetin addition to VEGF receptors—some of those pathways that are felt to be important for resistance. For example, the cabozantinib also targets the MET pathway, whereas lenvatinib, from lenvatinib plus everolimus, is not only a good inhibitor for VEGF receptor and platelet drive growth factor receptor as well, but also targets the FGF family of receptors.
Transcript edited for clarity.
A Japanese-American Male With Recurrent RCC